Abderrahmane Laadem

Abderrahmane Laadem, MD, currently serves as Vice President and Head of Oncology Late-Stage Development II and Hematology at Daiichi Sankyo, Inc., a position held since June 2020, and also holds the role of Global Head of Early Clinical Development in Oncology and Hematology. Prior to this, Abderrahmane Laadem was Vice President of Medical Affairs and Head of the Myeloid Portfolio at Bristol Myers Squibb from September 2019 to June 2020. Experience at Celgene as Executive Director and Sr. Director in Clinical Development for Hematology-Oncology spanned nearly nine years. Additional roles include Global Safety Officer and Corporate Safety Officer for Oncology Development at Sanofi. Early career experiences include serving as a Medical Oncologist in a Bone Marrow Transplant unit and Sr. Clinical Lead at various institutions, alongside a fellowship in medical oncology. Abderrahmane Laadem obtained an MD in Medical Oncology from Université Paris 13 and an MD from the University of Constantine.